EUS-guided treatment for nonfunctional pancreatic neuroendocrine tumors
Endoscopic Ultrasound-guided Fine-needle Injection for Nonfunctional Pancreatic Neuroendocrine Tumors: a Prospective Multicenter Study
This study is testing whether a new, less invasive treatment using ultrasound-guided injections can safely help people with nonfunctional pancreatic neuroendocrine tumors instead of traditional surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Guangxi Medical University Academic / other |
| Locations | 1 site (Nanning, Guangxi) |
| Trial ID | NCT05566093 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility, safety, and efficacy of endoscopic ultrasonography-guided fine-needle injection (EUS-FNI) for treating nonfunctional pancreatic neuroendocrine tumors (NF-pNETs). Traditionally, surgical resection has been the standard treatment, but it carries a high risk of postoperative complications. The study aims to explore whether EUS-FNI using ethanol or lauromacrogol can provide a safer alternative. It is a multicenter prospective study designed to gather comprehensive data on this innovative approach.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with NF-pNETs who either refuse surgery or are not suitable for surgical intervention.
Not a fit: Patients who are unsuitable for EUS-FNI due to poor health conditions or other contraindications may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a less invasive option for patients with NF-pNETs, potentially reducing the risks associated with surgery.
How similar studies have performed: Previous studies have indicated that EUS-FNI may be effective for treating pancreatic neuroendocrine tumors, suggesting a promising avenue for further exploration.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with NF-pNETs are evaluated by cytology or immunohistochemistry. 2. Patients who refuse surgery or observation. 3. Patients who have given their fully informed consent. Exclusion Criteria: 1. Patients who are not suitable for EUS-FNI. 2. Patients who have poor conditions including blood coagulation dysfunction, mental disorders, and mild or severe cardiorespiratory.
Where this trial is running
Nanning, Guangxi
- First Affiliated Hospital of Guangxi Medical University — Nanning, Guangxi, China (Recruiting)
Study contacts
- Principal investigator: Shanyu Qin, MD,Ph.D — First Affiliated Hospital of Guangxi Medical University
- Study coordinator: Shanyu Qin, MD,Ph.D
- Email: qsy0511@163.com
- Phone: 86-771-5353725
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.